Prosecution Insights
Last updated: April 19, 2026
Application No. 18/325,567

SUSTAINED FORMULATION FOR PREVENTION OR TREATMENT OF AUTOIMMUNE DISEASE CONTAINING NALTREXONE AND METHOD USING THE SAME

Final Rejection §112§DP
Filed
May 30, 2023
Examiner
AZPURU, CARLOS A
Art Unit
1617
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Inventage Lab Inc.
OA Round
4 (Final)
84%
Grant Probability
Favorable
5-6
OA Rounds
2y 9m
To Grant
94%
With Interview

Examiner Intelligence

Grants 84% — above average
84%
Career Allow Rate
1067 granted / 1276 resolved
+23.6% vs TC avg
Moderate +10% lift
Without
With
+10.3%
Interview Lift
resolved cases with interview
Typical timeline
2y 9m
Avg Prosecution
23 currently pending
Career history
1299
Total Applications
across all art units

Statute-Specific Performance

§101
1.1%
-38.9% vs TC avg
§103
23.0%
-17.0% vs TC avg
§102
18.4%
-21.6% vs TC avg
§112
29.8%
-10.2% vs TC avg
Black line = Tech Center average estimate • Based on career data from 1276 resolved cases

Office Action

§112 §DP
Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Withdrawn Rejection(s) The rejections under 35 USC 112, first and second paragraphs, double patenting, and 35 USC 103 over Sherman are withdrawn in view of applicant’s amendment, and filing of terminal disclaimers on 01/07/2026. The following rejection is based on the amendment of 01/07/2026: Claim Rejections - 35 USC § 112 The following is a quotation of 35 U.S.C. 112(b): (b) CONCLUSION.—The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the inventor or a joint inventor regards as the invention. The following is a quotation of 35 U.S.C. 112 (pre-AIA ), second paragraph: The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention. Claims 1-11 are rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor (or for applications subject to pre-AIA 35 U.S.C. 112, the applicant), regards as the invention. Claims 1 and 9 both refer to “at least about 3 weeks”. This term is indefinite because it is an open ended time period which could potentially entail an infinite amount of time. Correction is requested. Conclusion No claims are allowed. Applicant's amendment necessitated the new ground(s) of rejection presented in this Office action. Accordingly, THIS ACTION IS MADE FINAL. See MPEP § 706.07(a). Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a). A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any nonprovisional extension fee (37 CFR 1.17(a)) pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action. Correspondence Any inquiry concerning this communication or earlier communications from the examiner should be directed to CARLOS A AZPURU whose telephone number is (571)272-0588. The examiner can normally be reached 9 am- 3 pm, 4 pm-8pm. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Sue X Liu can be reached at 571-272-5539. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /CARLOS A AZPURU/Primary Examiner, Art Unit 1617 caz
Read full office action

Prosecution Timeline

May 30, 2023
Application Filed
Jul 28, 2023
Response after Non-Final Action
Feb 28, 2025
Non-Final Rejection — §112, §DP
Jun 04, 2025
Response Filed
Jun 18, 2025
Final Rejection — §112, §DP
Sep 25, 2025
Request for Continued Examination
Oct 02, 2025
Response after Non-Final Action
Oct 03, 2025
Non-Final Rejection — §112, §DP
Jan 07, 2026
Response Filed
Jan 23, 2026
Final Rejection — §112, §DP (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12589166
COMPOSITIONS AND METHODS FOR TREATING WOUNDS
2y 5m to grant Granted Mar 31, 2026
Patent 12582602
Tableted Cannabinoid Chewing Gum With Tableted Modules
2y 5m to grant Granted Mar 24, 2026
Patent 12569571
SALT RESPONSIVE NANOGELS AND NANOPARTICLES
2y 5m to grant Granted Mar 10, 2026
Patent 12569441
MICROPARTICLES AND NANOPARTICLES HAVING NEGATIVE SURFACE CHARGES
2y 5m to grant Granted Mar 10, 2026
Patent 12569457
COATED BETA HYDROXYBUTYRIC ACID CRYSTAL AND METHODS FOR PRODUCING THE SAME
2y 5m to grant Granted Mar 10, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

AI Strategy Recommendation

Get an AI-powered prosecution strategy using examiner precedents, rejection analysis, and claim mapping.
Powered by AI — typically takes 5-10 seconds

Prosecution Projections

5-6
Expected OA Rounds
84%
Grant Probability
94%
With Interview (+10.3%)
2y 9m
Median Time to Grant
High
PTA Risk
Based on 1276 resolved cases by this examiner. Grant probability derived from career allow rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month